Pantoprazole Articles
US sales boost 1st-qtr profits at Altana
12 May 2003
Colorado Medicaid sets eight-drug limit
5 May 2003
Profits up at Wyeth, HRT sales still suffering
28 April 2003
2002 profits up 27% at Altana on strong sales
24 March 2003
High US co-pays "are driving PPI switches"
17 February 2003
Earnings up at Wyeth, HRT drugs sluggish
3 February 2003
Altana AG sees 2002 sales grow 13%
3 February 2003
Altana net income up 25% in first half
12 August 2002
Altana boosts Protonix forecast
5 August 2002
Wyeth EPS increases 25% during 2nd qtr
29 July 2002
Pretax profits leap 41% at Altana
1 April 2002
Stock Commentary - Europe
11 February 2002
Expensive new GERD drugs "actually more cost-effective"
28 January 2002
Recordati buys drug rights for Italy
14 January 2002
Delay expected for Altana's roflumilast?
28 November 2001
Pantoprazole sales leap 144% as Altana raises 2001 profit forecast
27 November 2001
Schwarz Pharma looks to have turned corner
12 November 2001
FDA OKs AHP's Protonix IV for new indication
25 October 2001
AHP takes $950 mill fen-phen charge
24 October 2001
Byk Canada launches website
1 October 2001
Altana raises forecast after strong first half
15 August 2001
AHP posts 16% 1st-qtr earnings rise, sales up 6%
25 July 2001
Stock Commentary - Europe
28 June 2001
FDA expands Protonix indication
15 June 2001
Nexium makes strong start in USA
24 May 2001
AHP's Protonix IV launched in the USA
21 May 2001
New drug sales boost AHP's 1st-qtr profits
26 April 2001
Stock Commentary - Europe
5 April 2001
US HMOs reveal their most-accepted drugs
5 April 2001
Altana, AHP get FDA OK for Protonix IV
26 March 2001
Altana hit by problem with late-stage drug
14 March 2001
Schwarz Pharma net income up 65% as operating loss narrows
21 February 2001
AHP posts healthy 2nd quarter results
24 July 2000
FDA backs AHP's delayed-release Protonix
3 February 2000
Strong growth in 1999 for Altana
2 February 2000
Shares in Altana drop on AstraZeneca filing
9 December 1999
Stock Commentary Europe
2 September 1999
Altana's first half earnings move up 12%
11 August 1999
Pantoprazole "approvable" in USA
1 July 1999
AstraZeneca sues Azupharma over Losec
6 May 1999
Altana: life after pantoprazole?
7 April 1999
Pharma profits hit 213 mill DM at Altana AG
29 March 1999
Sun Pharma introduces nine new drugs
12 March 1999
Nycomed Amersham profits climb 12%
10 March 1999
Strong sales rise in 1998 for Altana
3 February 1999
AstraZeneca's Effect On Rest Of Pharma Sector
17 December 1998
Pantoprazole Driving Sales At Altana
13 November 1998
Altana Expands Overseas Thanks To Pantoprazole
13 August 1998
Altana In China
16 July 1998
Altana JV With India's Zydus On Pantoprazole
14 July 1998
Altana Expects 11% 1st Qtr Sales Increase
30 March 1998
Altana's Growth From Foreign Sales
13 February 1998
Knoll's High Hopes For Its Obesity Drug Sibutramine
15 January 1998
Eisai's Rabeprazole Debuts In Japan
5 January 1998
Double-Digit Sales Growth For Altana
11 November 1997
Amersham International And Nycomed To Merge
2 July 1997
Altana Pharma Posts Strong 1996 Growth
26 March 1997
1996 Sales Up 11.9% At Synthelabo
27 January 1997
Protium UK Launch
4 November 1996
Boots Buy Boosts BASF In 1996 First Half
2 September 1996
Currency-Related Distortions Hit Astra
2 September 1996
Sales Up 10%At Synthelabo
5 August 1996
Byk Gulden Forecasts Pantoprazole Sales
24 June 1996
Knoll Receives UK Clearance For Pantoprazole
24 June 1996
Astra And Byk Gulden End PPI Dispute
17 June 1996
Astra Building Prioritized Therapeutic Areas
20 November 1995
Byk Gulden gets Astra writ for omeprazole infringement
6 November 1995
Ivax Nycomed, A Defensive Merger?
6 November 1995
Astra AB: Nycomed AB pantoprazole injunction
2 October 1995
Astra Files Suit Against Byk Gulden
3 April 1995
New Chemical Entities Round-Up For 1994
6 February 1995
Japanese News In Brief
23 January 1995
Eradication Therapy For Helicobacter Pylori
10 October 1994
Hafslund And Byk Gulden Settle Dispute
26 September 1994
Altana's Profit Rises 20%
12 September 1994
Byk Gulden Receives Approval In Sweden
22 August 1994
ALTANA PHARMA GROWTH OVERSEAS
20 June 1994
ALTANA FORECAST FOREIGN GROWTH
18 April 1994
ALTANA PLANS DRUG INNOVATION OFFENSIVE
13 December 1993
ANANXYL WITHDRAWN FROM MARKET IN FRANCE
1 November 1993
GASTROENTEROLOGY CONFERENCE REPORT
26 July 1993
GROWTH AHEAD ALTANA WITH REBOUND IN 1994
7 June 1993
GLOBAL SALES OF H2 BLOCKERS TO DECLINE?
1 March 1993
"A TIME OF CHANGE" AT GERMANY'S ALTANA
22 June 1992
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
